What is LUNG's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.13B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for LUNG?

P/E (TTM) is n/a and 52-week range is $1.13 to $2.89 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s LUNG figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for LUNG?

The company profile lists revenue (TTM) near $88M, net income (TTM) near -$4.87B, EPS (TTM) near -$1.16 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Pulmonx Corporation based, and what identifiers does Chartloom list?

The company context section lists headquarters in Redwood City, California, US, 43M shares outstanding, ISIN US7458481014 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Pulmonx Corporation

$LUNG

Health Care · Health Care Equipment & Supplies

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Pulmonx Corp. is a medical technology company, which engages in the provision of interventional pulmonology, planning tools and treatments for obstructive lung diseases. The company is headquartered in Redwood City, California and currently employs 296 full-time employees. The company went IPO on 2020-10-01. The firm provides minimally invasive treatments for chronic obstructive pulmonary disease (COPD). The Company’s Zephyr Endobronchial Valve, Chartis Pulmonary Assessment System, LungTraX Platform, and StratX Lung Analysis Report are designed to assess and treat patients with severe emphysema/COPD. The LungTraX Platform is a cloud-based quantitative CT (QCT) analysis service that provides physicians with multiple products, LungTraX Connect, to improve workup efficiency, LungTraX Detect, to enable patient identification and an easy-to-read StratX Lung report that it designed for its solution that includes information on emphysema destruction, fissure completeness and lobar volume to help identify target lobes for treatment with Zephyr Valves. The Chartis System is a proprietary balloon catheter and console system with flow and pressure sensors designed to assess the presence of collateral ventilation.

Employees

296

Website

pulmonx.com/

IPO

2020-10-01

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US7458481014

Headquarters

Redwood City, California, US

Shares outstanding

43M

NAICS sector

Manufacturing

Institutional ownership

62.66%

Browse other companiesFree AI scores and summaries for more stocks